GFAP and chronic kidney disease: However, the CKD group treated with AST-120 exhibited a significant decrease in the double labeling of AQP4 and GFAP in blood vessels compared to the untreated CKD group (CA1, F1,9 = 9.345, p < 0.001; DG, F1,9 = 15.89, p < 0.001, arrows; Figure 8(C3,C4,C7,C8),E,F).